Unknown

Dataset Information

0

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-?-based regimens.


ABSTRACT: Pegylated interferon-? (PEG-IFN-? or PEG-IFN 2a and 2b)- and ribavirin (RBV)-based regimens are the mainstay for treatment of hepatitis C virus (HCV) genotype 1. IFNL3 (IL28B) genotype is the strongest baseline predictor of response to PEG-IFN-? and RBV therapy in previously untreated patients and can be used by patients and clinicians as part of the shared decision-making process for initiating treatment for HCV infection. We provide information regarding the clinical use of PEG-IFN-?- and RBV-containing regimens based on IFNL3 genotype.

SUBMITTER: Muir AJ 

PROVIDER: S-EPMC3904555 | biostudies-literature | 2014 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens.

Muir A J AJ   Gong L L   Johnson S G SG   Lee M T M MT   Williams M S MS   Klein T E TE   Caudle K E KE   Nelson D R DR  

Clinical pharmacology and therapeutics 20131004 2


Pegylated interferon-α (PEG-IFN-α or PEG-IFN 2a and 2b)- and ribavirin (RBV)-based regimens are the mainstay for treatment of hepatitis C virus (HCV) genotype 1. IFNL3 (IL28B) genotype is the strongest baseline predictor of response to PEG-IFN-α and RBV therapy in previously untreated patients and can be used by patients and clinicians as part of the shared decision-making process for initiating treatment for HCV infection. We provide information regarding the clinical use of PEG-IFN-α- and RBV-  ...[more]

Similar Datasets

| S-EPMC5474211 | biostudies-literature
| S-EPMC4481158 | biostudies-literature
| S-EPMC4026598 | biostudies-literature
| S-EPMC4111801 | biostudies-literature
| S-EPMC5546947 | biostudies-literature
| S-EPMC5931215 | biostudies-literature
| S-EPMC4785051 | biostudies-literature
| S-EPMC3289963 | biostudies-literature
| S-EPMC4675696 | biostudies-literature
| S-EPMC6739160 | biostudies-literature